Skye Bioscience, Inc. filed its 10-K on Mar 31, 2023 for the period ending Dec 31, 2022. In this report its auditor, Marcum LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.06 USD | +0.84% | +0.50% | +343.38% |
May. 10 | Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 23 | Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Transportation Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+343.38% | 338M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.98% | 40.65B | |
-10.87% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- EMBI Stock
- News Skye Bioscience, Inc.
- Skye Bioscience, Inc. Auditor Raises 'Going Concern' Doubt